Table I.
Baseline characteristics of patients.
| Characteristics | Total (n=70) | SNR (n=27) | DNR (n=30) | NR (n=13) | P-value |
|---|---|---|---|---|---|
| Age, years (%) | 0.203 | ||||
| <70 | 49 (70.0%) | 18 (66.7%) | 24 (80.0%) | 7 (53.8%) | – |
| ≥70 | 21 (30.0%) | 9 (33.3%) | 6 (20.0%) | 6 (46.2%) | – |
| Sex (%) | 0.880 | ||||
| Male | 56 (80.0%) | 21 (77.8%) | 24 (80.0%) | 11 (84.6%) | – |
| Female | 14 (20.0%) | 6 (22.2%) | 6 (20.0%) | 2 (15.4%) | – |
| ECOG PS score (%) | 0.112 | ||||
| 0 | 21 (30.0%) | 10 (37.0%) | 9 (30.0%) | 2 (15.4%) | – |
| 1 | 35 (50.0%) | 14 (51.9%) | 16 (53.3%) | 5 (38.4%) | – |
| 2 | 14 (20.0%) | 3 (11.1%) | 5 (16.7%) | 6 (46.2%) | – |
| Tumor location (%) | 0.091 | ||||
| Upper thoracic | 21 (30.0%) | 5 (18.5%) | 13 (43.3%) | 3 (23.1%) | – |
| Middle thoracic | 34 (48.6%) | 13 (48.1%) | 12 (40.0%) | 9 (69.2%) | – |
| Lower thoracic | 15 (21.4%) | 9 (33.3%) | 5 (16.7%) | 1 (7.7%) | – |
| Tumor length, cm (range) | 5 (2–12) | 5 (2–9) | 6 (2–12) | 5 (3–8) | 0.727 |
| Clinical stage (%) | 0.367 | ||||
| II | 20 (28.6%) | 9 (33.3%) | 6 (20.0%) | 5 (38.5%) | – |
| III | 50 (71.4%) | 18 (66.7%) | 24 (80.0%) | 8 (61.5%) | – |
| T stage (%) | 0.059a | ||||
| T1 | 2 (2.9%) | 1 (3.7%) | 1 (3.3%) | 0 | – |
| T2 | 5 (7.1%) | 4 (14.8%) | 1 (3.3%) | 0 | – |
| T3 | 18 (25.7%) | 8 (29.6%) | 4 (13.3%) | 6 (46.2%) | – |
| T4 | 45 (64.3%) | 14 (62.9%) | 24 (80%) | 7 (53.8%) | – |
| N stage (%) | 0.167 | ||||
| N0 | 32 (45.7%) | 13 (48.1%) | 20 (66.7%) | 5 (38.5%) | – |
| N1-3 | 38 (54.3%) | 14 (51.9%) | 10 (33.3%) | 8 (61.5%) | – |
| Radiation dose, Gy (%) | 0.113 | ||||
| 60 | 30 (42.9%) | 8 (29.6%) | 17 (56.7%) | 5 (38.5%) | – |
| >60 | 40 (57.1%) | 19 (70.4%) | 13 (43.3%) | 8 (61.5%) | – |
| Chemotherapy cycle (%) | 0.239 | ||||
| 2 | 39 (55.7%) | 12 (44.4%) | 20 (66.7%) | 7 (53.8%) | – |
| ≥3 | 31 (44.3%) | 15 (55.6%) | 10 (33.3%) | 6 (46.2%) | – |
a
T1-3 vs. T4. DNR, docetaxel, nedaplatin and radiotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; NR, nedaplatin and radiotherapy; SNR, S-1, nedaplatin and radiotherapy.